AstraZeneca (AZN) has released an update.
AstraZeneca and Daiichi Sankyo’s drug Enhertu has received US approval as the first tumour-agnostic HER2-directed therapy for metastatic HER2-positive solid tumours after prior systemic treatment. This accelerated approval is contingent on further clinical trials and builds on the drug’s five existing indications. Enhertu’s approval, based on positive Phase II trial results, signifies a new treatment option for patients with few alternatives and underscores the importance of biomarker testing in advanced cancers.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
